

Supplementary material for:

## Cyano-B12 or whey powder with endogenous hydroxo-B12 for supplementation in B12 deficient lactovegetarians

Sadanand Naik <sup>1\*</sup>, Namita Mahalle <sup>1</sup>, Eva Greibe <sup>2</sup>, Marie S. Ostenfeld <sup>3</sup>, Christian W. Heegaard <sup>4</sup>, Ebba Nexø <sup>2</sup> and Sergey N. Fedosov <sup>4\*</sup>

<sup>1</sup> Department of Pathology, Deenanath Mangeshkar Hospital and Research Center, Pune, India; [pnmahalle@gmail.com](mailto:pnmahalle@gmail.com) (N.M.)

<sup>2</sup> Department of Clinical Biochemistry and Institute of Clinical Medicine, Aarhus University Hospital, DK-8200 Aarhus N, Denmark; [evagreibe@gmail.com](mailto:evagreibe@gmail.com) (E.G.); [ebbanexo@rm.dk](mailto:ebbanexo@rm.dk) (E.N.)

<sup>3</sup> Arla Foods Ingredients Group P/S, DK-8260 Viby, Denmark; [marie.stampe.ostenfeld@arlafoods.com](mailto:marie.stampe.ostenfeld@arlafoods.com) (M.S.O)

<sup>4</sup> Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark; [cwh@mbg.au.dk](mailto:cwh@mbg.au.dk) (C.W.H)

\* Correspondence: [sadu\\_naik@rediffmail.com](mailto:sadu_naik@rediffmail.com) (S.N.); [snf@mbg.au.dk](mailto:snf@mbg.au.dk) (S.N.F.); Tel: +91 20 66023194 (S.N.); +45 87155521 (S.N.F.)

**Supplementary Table S1. Nutritional composition of whey powder (Lacprodan® DI-8290) as per manufacturer's<sup>a</sup> product specifications.**

Composition	Amount (dry basis)
Protein %	81,5
Lactose %	2
Fat %	8
Ash %	2.2

<sup>a</sup>Lacprodan® DI-8290 was procured by Arla Foods Ingredients Group P/S, Viby, Denmark.

**Supplementary Table S2.** Fitting parameters of the markers, responding to the treatment with CN-B12 capsules, or whey powder.

Treatment and $P_i$ number	CN-B12 capsules fitting $P_i$ ( $p$ of reference value)		whey powder fitting $P_i$ ( $p$ of reference value)	
$\Delta B12$	Equation 1			
$P_1 \pm SE_1$	$0.0 \pm 18$	(1.0)	$0.0 \pm 4.1$	1.0
$P_2 \pm SE_2$	$97 \pm 20$	$(7 \cdot 10^{-6})$	$47 \pm 13$	0.0003
$P_3 \pm SE_3$	$0.69 \pm 0.42$	(0.1)	$0.29 \pm 0.21$	0.17
( $p$ overall)		<b><math>(7 \cdot 10^{-8})</math></b>		<b><math>(5 \cdot 10^{-5})</math></b>
$\Delta \text{holoTC}$	Equation 2			
$P_1 \pm SE_1$	$0.0 \pm 5.0$	(1.0)	$0.0 \pm 2.8$	(1.0)
$P_2 \pm SE_2$	$60 \pm 10$	$(9 \cdot 10^{-8})$	$38 \pm 6$	$(3 \cdot 10^{-9})$
$P_3 \pm SE_3$	$8.0 \pm 0.9$	$(2 \cdot 10^{-13})$	$8.2 \pm 0.9$	$(8 \cdot 10^{-16})$
( $p$ overall)		<b><math>(2 \cdot 10^{-20})</math></b>		<b><math>(3 \cdot 10^{-24})</math></b>
R(Hcy)	Equation 2			
$P_1 \pm SE_1$	$1.00 \pm 0.04$	(1.0)	$1.00 \pm 0.02$	(1.0)
$P_2 \pm SE_2$	$-0.38 \pm 0.09$	$(4 \cdot 10^{-5})$	$-0.47 \pm 0.07$	$(6 \cdot 10^{-9})$
$P_3 \pm SE_3$	$9.4 \pm 1.6$	$(9 \cdot 10^{-8})$	$6.8 \pm 0.7$	$(1 \cdot 10^{-17})$
( $p$ overall)		<b><math>(4 \cdot 10^{-12})</math></b>		<b><math>(6 \cdot 10^{-26})</math></b>
R(MMA)	Equation 2			
$P_1 \pm SE_1$	$1.00 \pm 0.06$	(1.0)	$1.00 \pm 0.05$	(1.0)
$P_2 \pm SE_2$	$-0.67 \pm 0.12$	$(1 \cdot 10^{-7})$	$-0.34 \pm 0.07$	$(4 \cdot 10^{-6})$
$P_3 \pm SE_3$	$8.2 \pm 1.0$	$(4 \cdot 10^{-13})$	$6.4 \pm 1.1$	$(1 \cdot 10^{-7})$
( $p$ overall)		<b><math>(5 \cdot 10^{-20})</math></b>		<b><math>(4 \cdot 10^{-13})</math></b>

The bold figures for the overall probabilities highlight the high levels of significance for deviation from a “zero response”.